Mergers & acquisitions
Investors and analysts are wondering if the company should buy a biotech to bolster its pipeline and bottom line.
Fosun Pharma said it would buy Tridem Pharma S.A.S. for $73M, in a move to expand its market share in Europe and Africa.
As part of consolidation program, Shire is looking to sell a manufacturing facility in Milford, MA that it gained through its 2015 acquisition of Baxalta.
Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9B acquisition of Advanced Accelerator Applications.
Merck released its third-quarter financial results today, and along with it a hint--just a hint--that there might be some M&A deals in the future.
Shares of Neos Therapeutics have soared more than 38 percent this morning after PDL BioPharma announced its intention to acquire the company in an all-cash deal that could total about $287M.
Earlier this month, Pfizer’s chairman and CEO, Ian Read, said he was considering selling the company’s Consumer Healthcare business, or possibly spinning it off.
Stryker picked up controlling interest in Vexim, a French medical device company that specializes in the minimally invasive treatment of vertebral fractures.
Danish company Ambu plopped down $265M to acquire Germany-based Invendo Medical, a privately-held medtech company that develops single-use high definition endoscopy products.
WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.
PRESS RELEASES